Clinical Trial Search

Primary: Continuous Apposition of the Skin Edges Without Wound Dehiscence or Re-closure as Measured by the Upper Limit of 95% Confidence Interval in Proportion of Successes for…

Primary: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. — 91.7; 53.4; 93.3; 63.8 percentage of participants

Primary: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. — 89.7; 80.0; 89.7; 71.7 Percentage of participants

Primary: Number of Participants Not Smoking in the Previous 7 Days, Confirmed by Expired Carbon Monoxide Reading < 10 Parts Per Million at Week 52 — 10; 11 participants

Primary: Pain on Movement — 19.5; 56.9 mm

Primary: Week 24 Change in Percentage of CD8+ T Cells That Co-express CD38 and HLA DR (Week 24 %CD38+HLA-DR+ CD8+ T Cells Minus Baseline %CD38+HLA-DR+ CD8+ T Cells) — 2.2; -0.7…

Primary: Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to End of Treatment (Day 21) — -20.72 Scores on a scale

Primary: Positive Symptom Item Scores by Week and Treatment Group — 15.5; 15.5; 14.6; 15.1 units on a scale

Primary: Geometric Mean Antibody Titres for Haemagglutination Inhibition (HI) Antibodies Against Fluarix Vaccine Containing H1N1 Strain. — 150.1; 150.3; 646.8; NA Titres

Primary: Percentage of Patients That Experience 10% Decline in Triglycerides From Baseline to Week 24. — 80; 73 percentage of patients

Primary: Brain Oxygenation Level Dependent Signal in the Fusiform Gyrus and the Amygdala on Concerta vs. Placebo — 1.79; 0.58; 1.43; 0.77 Face-Shape BOLD signal difference

Primary: Adjudicated Composite Rate of All Death, All MI and Target Vessel Revascularization (TVR). — 21.5; 22 Percentage of Participants

Primary: Serum Level of Acetaminophen-cysteine (APAP-Cys) Protein Adducts — 0.0; 0.3; 0.3; 0.4 nmol/mL

Primary: Aqueous Humor Flare — 8.4; 9.3; 11.4; 8.4 photons/msec

Primary: Adherence — 63; 43 percentage of adherent patients